alpha-synuclein has been researched along with Lupus-Erythematosus--Systemic* in 2 studies
1 trial(s) available for alpha-synuclein and Lupus-Erythematosus--Systemic
Article | Year |
---|---|
Role of alpha-synuclein in autophagy modulation of primary human T lymphocytes.
It has been demonstrated that α-synuclein can aggregate and contribute to the pathogenesis of some neurodegenerative diseases and it is capable of hindering autophagy in neuronal cells. Here, we investigated the implication of α-synuclein in the autophagy process in primary human T lymphocytes. We provide evidence that: (i) knocking down of the α-synuclein gene resulted in increased autophagy, (ii) autophagy induction by energy deprivation was associated with a significant decrease of α-synuclein levels, (iii) autophagy inhibition by 3-methyladenine or by ATG5 knocking down led to a significant increase of α-synuclein levels, and (iv) autophagy impairment, constitutive in T lymphocytes from patients with systemic lupus erythematosus, was associated with abnormal accumulation of α-synuclein aggregates. These results suggest that α-synuclein could be considered as an autophagy-related marker of peripheral blood lymphocytes, potentially suitable for use in the clinical practice. Topics: Adult; Aged; alpha-Synuclein; Autophagy; Biomarkers; Female; Gene Knockdown Techniques; Humans; Lupus Erythematosus, Systemic; Male; Middle Aged; T-Lymphocytes | 2014 |
1 other study(ies) available for alpha-synuclein and Lupus-Erythematosus--Systemic
Article | Year |
---|---|
Transcriptomics in tissue glucocorticoid sensitivity.
Synthetic glucocorticoids are widely used in the treatment of several inflammatory, autoimmune and lymphoproliferative disorders. However, considerable variation in response to therapeutic doses of glucocorticoids has been documented among individuals. The aim of our study was to identify novel glucocorticoid sensitivity-determining genes using genome-wide expression profiling in healthy subjects.. One hundred one healthy subjects [mean age ± standard error of the mean (SEM); 26.52 ± 0.50 years] were given 0.25 mg dexamethasone at midnight, and serum cortisol concentrations were determined at 08:00 hours the following morning. Subjects were stratified into the 10% most glucocorticoid-sensitive and 10% most glucocorticoid-resistant according to the serum cortisol concentrations. Genomic DNA, RNA and plasma samples were obtained in the 22 subjects one month later.. Transcriptomic analysis showed variability between glucocorticoid-resistant and glucocorticoid-sensitive subjects. One hundred thirty-three genes were upregulated and 49 downregulated in the glucocorticoid-resistant compared to the glucocorticoid-sensitive group. Further analysis revealed differences between 3 glucocorticoid-resistant and 3 glucocorticoid-sensitive subjects. The majority of the 1058 upregulated genes and 1139 downregulated genes were found to participate in telomere maintenance, systemic lupus erythematosus and Alzheimer's disease. Interestingly, Synuclein A, a key molecule in Parkinson's disease, was upregulated in the subgroup of glucocorticoid-sensitive subjects.. We have identified differences in tissue sensitivity to glucocorticoids among healthy subjects at the transcriptomic level. These differences are associated with differential expression of genes related to autoimmune and neurological disorders. Topics: Adult; alpha-Synuclein; Alzheimer Disease; Dexamethasone; Down-Regulation; Female; Gene Expression Profiling; Glucocorticoids; Humans; Hydrocortisone; Lupus Erythematosus, Systemic; Male; Receptors, Glucocorticoid; Telomere Homeostasis; Transcriptome; Up-Regulation | 2019 |